CONNECT trial results, coverage expansion seen fueling DXCM growth
CONNECT trial results and expanded coverage are expected to drive DXCM growth, with CMS decisions anticipated by mid-2027. Product innovation, including a 15-Day sensor and AI features, supports margin expansion and global adoption.
Strong CONNECT trial results and expanded coverage are expected to drive growth, with CMS decisions anticipated by mid-2027. Product innovation, including the 15-Day sensor and AI-driven features, is expected to support margin expansion and global adoption. Financial guidance remains at 10%+ growth, with margin…